NURIX THERAPEUTICS, INC. Proceeds from Stock Options Exercised
NURIX THERAPEUTICS, INC. (NRIX) reported Proceeds from Stock Options Exercised of $441.00 thousand for the 6-month period ending 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2026-07-09
- NURIX THERAPEUTICS, INC. proceeds from stock options exercised for the quarter ending 2026-05-31 was $66.00K, a 1000.00% increase year-over-year.
- NURIX THERAPEUTICS, INC. proceeds from stock options exercised for the quarter ending 2026-02-28 was $375.00K, a 69.68% increase year-over-year.
- NURIX THERAPEUTICS, INC. proceeds from stock options exercised for the quarter ending 2025-08-31 was $178.00K, a 94.14% decline year-over-year.
- NURIX THERAPEUTICS, INC. proceeds from stock options exercised for the quarter ending 2025-05-31 was $6.00K, a 97.22% decline year-over-year.
- NURIX THERAPEUTICS, INC. proceeds from stock options exercised for fiscal 2022 was $1.08M, a 35.29% decline from fiscal 2021.
- NURIX THERAPEUTICS, INC. proceeds from stock options exercised for fiscal 2021 was $1.67M, a 71.75% increase from fiscal 2020.
- NURIX THERAPEUTICS, INC. proceeds from stock options exercised for fiscal 2020 was $970.00K, a 583.10% increase from fiscal 2019.
- NURIX THERAPEUTICS, INC. proceeds from stock options exercised for fiscal 2019 was $142.00K.
| Period end | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 6 month | Proceeds from Stock Options Exercised 9 month | Proceeds from Stock Options Exercised 12 month |
|---|---|---|---|---|
| 2026-05-31 | $66.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-09 | $441.00K 10-Q · filed 2026-07-09 | ||
| 2026-02-28 | $375.00K 10-Q · filed 2026-04-08 | |||
| 2025-08-31 | $178.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-09 | $184.00K derived: sum of 2 quarters · filed 2026-07-09 | $405.00K 10-Q · filed 2025-10-09 | |
| 2025-05-31 | $6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-09 | $227.00K 10-Q · filed 2026-07-09 | ||
| 2025-02-28 | $221.00K 10-Q · filed 2026-04-08 | |||
| 2024-08-31 | $3.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-09 | $3.25M derived: sum of 2 quarters · filed 2025-10-09 | $3.61M 10-Q · filed 2025-10-09 | |
| 2024-05-31 | $216.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-09 | $571.00K 10-Q · filed 2025-07-09 | ||
| 2024-02-29 | $355.00K 10-Q · filed 2025-04-08 | |||
| 2023-05-31 | $25.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-11 | $53.00K 10-Q · filed 2024-07-11 | $101.00K derived: sum of 3 quarters · filed 2024-07-11 | $275.00K derived: sum of 4 quarters · filed 2024-07-11 |
| 2023-02-28 | $28.00K 10-Q · filed 2024-04-10 | $76.00K derived: sum of 2 quarters · filed 2024-04-10 | $250.00K derived: sum of 3 quarters · filed 2024-04-10 | $682.00K derived: sum of 4 quarters · filed 2024-04-10 |
| 2022-11-30 | $48.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $222.00K derived: sum of 2 quarters · filed 2023-02-09 | $654.00K derived: sum of 3 quarters · filed 2023-02-09 | $1.08M 10-K · filed 2023-02-09 |
| 2022-08-31 | $174.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-06 | $606.00K derived: sum of 2 quarters · filed 2022-10-06 | $1.03M 10-Q · filed 2022-10-06 | $1.53M derived: sum of 4 quarters · filed 2023-04-13 |
| 2022-05-31 | $432.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-07 | $856.00K 10-Q · filed 2022-07-07 | $1.36M derived: sum of 3 quarters · filed 2023-04-13 | $1.89M derived: sum of 4 quarters · filed 2023-04-13 |
| 2022-02-28 | $424.00K 10-Q · filed 2023-04-13 | $924.00K derived: sum of 2 quarters · filed 2023-04-13 | $1.46M derived: sum of 3 quarters · filed 2023-04-13 | $1.77M derived: sum of 4 quarters · filed 2023-04-13 |
| 2021-11-30 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $1.03M derived: sum of 2 quarters · filed 2023-02-09 | $1.35M derived: sum of 3 quarters · filed 2023-02-09 | $1.67M 10-K · filed 2023-02-09 |
| 2021-08-31 | $535.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-06 | $849.00K derived: sum of 2 quarters · filed 2022-10-06 | $1.17M 10-Q · filed 2022-10-06 | $1.20M derived: sum of 4 quarters · filed 2022-10-06 |
| 2021-05-31 | $314.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-07 | $631.00K 10-Q · filed 2022-07-07 | $664.00K derived: sum of 3 quarters · filed 2022-07-07 | $1.42M derived: sum of 4 quarters · filed 2022-07-07 |
| 2021-02-28 | $317.00K 10-Q · filed 2022-04-08 | $350.00K derived: sum of 2 quarters · filed 2022-04-08 | $1.11M derived: sum of 3 quarters · filed 2022-04-08 | $1.24M derived: sum of 4 quarters · filed 2022-04-08 |
| 2020-11-30 | $33.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | $793.00K derived: sum of 2 quarters · filed 2022-01-28 | $923.00K derived: sum of 3 quarters · filed 2022-01-28 | $970.00K 10-K · filed 2022-01-28 |
| 2020-08-31 | $760.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-14 | $890.00K derived: sum of 2 quarters · filed 2021-10-14 | $937.00K 10-Q · filed 2021-10-14 | $1.02M derived: sum of 4 quarters · filed 2022-01-28 |
| 2020-05-31 | $130.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-13 | $177.00K 10-Q · filed 2021-07-13 | $257.00K derived: sum of 3 quarters · filed 2022-01-28 | |
| 2020-02-29 | $47.00K 10-Q · filed 2021-04-13 | $127.00K derived: sum of 2 quarters · filed 2022-01-28 | ||
| 2019-11-30 | $80.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | $142.00K 10-K · filed 2022-01-28 | ||
| 2019-08-31 | $62.00K 10-Q · filed 2020-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |